Progress and Development in Treatment of Covid – 19, and Vaccine development: A Review

American Journal of PharmTech Research Pub Date : 2021-08-07 DOI:10.46624/ajptr.2021.v11.i4.005

V. P. Sonar, Priyanka V Dalvi, S. Chalikwar

{"title":"Progress and Development in Treatment of Covid – 19, and Vaccine development: A Review","authors":"V. P. Sonar, Priyanka V Dalvi, S. Chalikwar","doi":"10.46624/ajptr.2021.v11.i4.005","DOIUrl":null,"url":null,"abstract":"The entire world is facing a worst situation of pandemic ever. It’s been more than 18 months \nafter the initial reports on Covid from China, and the pandemic is still going. As per the data \navailable over the WHO website as of 23 June 2021, there have been 178,837,204 confirmed \ncases of COVID-19, including 3,880,450 deaths, reported to WHO. As of 21 June 2021, a total \nof 2,414,347,324 vaccine doses have been administered. Despite of having more than 15 \nvaccines for Covid-19; the challenge to treat a patient with a define line of treatment remains the \nsame. In the present review we have made an attempt to summarize the various medicines which \nare being used by medical practitioner in India and overseas. Use of different drug molecules like \nRemdesivir, Tocilzumab, Hydroxychloroquine, Azithromycine, Ivermectin, Steroids, \nDoxicycline, Ecosprine, Low molecular weight Heparin, Lopinavir and Ritonavir, Nitazoxanide, \nBaricitinib etc. were highlighted; although the list is long. A focus is made on the different types \nof vaccines available till date and their status in various countries. \nKeywords: Covid-19, Vaccine, Antiviral, Pandemic, Antibiotics.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of PharmTech Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46624/ajptr.2021.v11.i4.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The entire world is facing a worst situation of pandemic ever. It’s been more than 18 months after the initial reports on Covid from China, and the pandemic is still going. As per the data available over the WHO website as of 23 June 2021, there have been 178,837,204 confirmed cases of COVID-19, including 3,880,450 deaths, reported to WHO. As of 21 June 2021, a total of 2,414,347,324 vaccine doses have been administered. Despite of having more than 15 vaccines for Covid-19; the challenge to treat a patient with a define line of treatment remains the same. In the present review we have made an attempt to summarize the various medicines which are being used by medical practitioner in India and overseas. Use of different drug molecules like Remdesivir, Tocilzumab, Hydroxychloroquine, Azithromycine, Ivermectin, Steroids, Doxicycline, Ecosprine, Low molecular weight Heparin, Lopinavir and Ritonavir, Nitazoxanide, Baricitinib etc. were highlighted; although the list is long. A focus is made on the different types of vaccines available till date and their status in various countries. Keywords: Covid-19, Vaccine, Antiviral, Pandemic, Antibiotics.

查看原文本刊更多论文

新冠肺炎治疗进展及疫苗研制综述

整个世界正面临着有史以来最严重的流行病形势。中国首次报告新冠肺炎疫情已经过去了18个多月，疫情仍在持续。根据世卫组织网站上提供的截至2021年6月23日的数据，向世卫组织报告的COVID-19确诊病例为178,837,204例，其中包括3,880,450例死亡。截至2021年6月21日，共接种了2 414 347 324剂疫苗。尽管拥有超过15种Covid-19疫苗;用明确的治疗方法来治疗病人的挑战仍然是一样的。在目前的审查中，我们试图总结印度和海外医生正在使用的各种药物。重点介绍了瑞德西韦、托珠单抗、羟氯喹、阿奇霉素、伊维菌素、类固醇、多西环素、Ecosprine、低分子肝素、洛匹那韦和利托那韦、尼唑昔尼、巴西替尼等不同药物分子的使用情况;虽然名单很长。重点介绍了迄今为止可获得的不同类型的疫苗及其在各国的状况。关键词:Covid-19，疫苗，抗病毒，大流行，抗生素

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of PharmTech Research

自引率

0.00%

发文量